NEO Neogenomics Inc
Price (delayed)
$11.1
Market cap
$1.43B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.62
Enterprise value
$1.66B
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose
Highlights
Neogenomics's gross profit has increased by 19% YoY and by 3.4% QoQ
The revenue rose by 12% YoY and by 2.6% QoQ
The quick ratio has plunged by 69% YoY and by 2.2% from the previous quarter
The equity is down by 4.2% year-on-year
Key stats
What are the main financial stats of NEO
Market
Valuations
Earnings
Shares outstanding
128.46M
Market cap
$1.43B
Enterprise value
$1.66B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.58
Price to sales (P/S)
2.13
EV/EBIT
N/A
EV/EBITDA
224.44
EV/Sales
2.52
Revenue
$660.57M
Gross profit
$290.1M
Operating income
-$92.11M
Net income
-$78.73M
EBIT
-$74.06M
EBITDA
$7.42M
Free cash flow
-$34.04M
Per share
Balance sheet
Liquidity
EPS
-$0.62
EPS diluted
-$0.62
Free cash flow per share
-$0.27
Book value per share
$7.03
Revenue per share
$5.22
TBVPS
$6.12
Total assets
$1.64B
Total liabilities
$735.7M
Debt
$605.33M
Equity
$902.34M
Working capital
$294.78M
Debt to equity
0.67
Current ratio
1.98
Quick ratio
1.78
Net debt/EBITDA
32.14
Margins
Efficiency
Dividend
EBITDA margin
1.1%
Gross margin
43.9%
Net margin
-11.9%
Operating margin
-13.9%
Return on assets
-4.8%
Return on equity
-8.6%
Return on invested capital
-9.5%
Return on capital employed
-5.5%
Return on sales
-11.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NEO stock price
How has the Neogenomics stock price performed over time
Intraday
-6.41%
1 week
-23.02%
1 month
-21.72%
1 year
-32.65%
YTD
-32.65%
QTD
-32.65%
Financial performance
How have Neogenomics's revenue and profit performed over time
Revenue
$660.57M
Gross profit
$290.1M
Operating income
-$92.11M
Net income
-$78.73M
Gross margin
43.9%
Net margin
-11.9%
Neogenomics's operating margin has increased by 24% YoY and by 2.8% from the previous quarter
NEO's net margin is up by 20% YoY
Neogenomics's gross profit has increased by 19% YoY and by 3.4% QoQ
The company's operating income rose by 15% YoY
Growth
What is Neogenomics's growth rate over time
Valuation
What is Neogenomics stock price valuation
P/E
N/A
P/B
1.58
P/S
2.13
EV/EBIT
N/A
EV/EBITDA
224.44
EV/Sales
2.52
The company's EPS rose by 11% YoY
The price to book (P/B) is 54% less than the 5-year quarterly average of 3.4 and 25% less than the last 4 quarters average of 2.1
The equity is down by 4.2% year-on-year
The price to sales (P/S) is 64% lower than the 5-year quarterly average of 5.9 and 29% lower than the last 4 quarters average of 3.0
The revenue rose by 12% YoY and by 2.6% QoQ
Efficiency
How efficient is Neogenomics business performance
The company's return on sales rose by 26% YoY
NEO's ROIC is down by 9% since the previous quarter and by 4.4% year-on-year
The return on assets rose by 8% year-on-year but it has declined by 2.1% since the previous quarter
The return on equity has increased by 7% year-on-year but it has declined by 2.4% since the previous quarter
Dividends
What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NEO.
Financial health
How did Neogenomics financials performed over time
The total assets is 123% greater than the total liabilities
The quick ratio has plunged by 69% YoY and by 2.2% from the previous quarter
NEO's current ratio has plunged by 68% YoY
NEO's debt is 33% lower than its equity
The equity is down by 4.2% year-on-year
The debt to equity rose by 3.1% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.